Sun Pharma acquires Russian company for $60 million

Sun Pharma gained ownership of 85% of Biosintez's equity stake for $26 mn; it also owned a company debt of $36 mn

Drug major Sun Pharmaceutical Industries Ltd on Wednesday said it has entered into an agreement to acquire Russian pharma company JSC Biosintez for $24 million.

The Indian company will also assume Russian company's debt of $36 million, Sun Pharma said in a statement.

The total deal size works out to $60 million ($26 million for 85.1 per cent equity stake and $36 million Russian company's debt).

According to Sun Pharma, the acquisition will be done by its wholly owned subsidiary.

Biosintez is a Russian pharmaceutical company focusing on the hospital segment with annual revenues of approximately $52 million for 2015.

It has a manufacturing facility in Penza region with capabilities to manufacture a wide variety of dosage forms including pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories and others.

"This acquisition is consistent with Sun Pharma's philosophy to invest in strategic emerging markets. This transaction gives us access to local manufacturing capability across multiple dosage forms in Russia, enabling us to serve the Russia pharmaceutical market more effectively," Aalok Shanghvi, Head of Emerging Markets, Sun Pharma was quoted as saying in the statement.

The transaction, expected to be completed by end of 2016, is subject to the approval of the Russian Federal Anti-Monopoly Service and other closing conditions.